XML 16 R48.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Legal Proceedings (Details) (USD $)
 3 Months Ended 6 Months Ended
Apr. 03, 2011
Jul. 03, 2011
Jun. 28, 2009
Loss Contingencies [Line Items]      
Litigation Loss $ 593,000,000    
Net litigation expense   73,000,000  
Legal Proceeding (Textuals) [Abstract]      
Amount given to plaintiff by jury 482,000,000    
Verdict in favor of the State's Attorney General and against Janssen and the Company   257,700,000  
Litigation settlement pre judgment interest 111,000,000    
Approximate damages initially awarded to Centocor, then subsequently reversed by the Court of Appeals     1,700,000,000
Assessed damages for alleged consumer fraud as to DURAGESIC and RISPERDAL   4,500,000  
Settlement payment related fines disgorgement and interest   78,000,000  
Percentage of revenue represented by relinquished territories   30.00%  
One time payment received by Company   500,000,000  
Merck [Member]
      
Loss Contingencies [Line Items]      
Percentage of contribution to income profit split   58.00%  
Percentage of revenue represented by retained territories   70.00%  
Amount of revenue represented by retained territories   2,800,000,000  
COBI [Member]
      
Loss Contingencies [Line Items]      
Percentage of contribution to income profit split   42.00%  
Average Wholesale Price Litigation [Member] | Civil penalties [Member]
      
Loss Contingencies [Line Items]      
Litigation Loss   6,500,000  
Risperdal [Member] | Civil penalties [Member]
      
Loss Contingencies [Line Items]      
Litigation Loss   327,100,000  
Restitution [Member]
      
Loss Contingencies [Line Items]      
Litigation Loss   $ 45,000,000